Nicotine, tobacco and vaping products
nicotine · tobacco · cigarettes · smoking · vapes · vaping · e-cigarettes · electronic cigarettes · nicotine salts · nicotine pouches · e-liquid
What does current UK evidence show?
ONS estimates for 2025 show UK adult cigarette smoking continuing to decline and adult vaping in Great Britain broadly unchanged from 2024. These are different surveys and populations, not a single UK nicotine-use measure.
Overview
Identity, legal classification, form and pharmacological context
- Drug category
- Stimulants · Nicotine and tobacco
- Common names
- nicotine, tobacco, cigarettes, smoking, vapes, vaping, e-cigarettes, electronic cigarettes, nicotine salts, nicotine pouches, e-liquid
- Typical forms
- Cigarettes, hand-rolling tobacco and other tobacco products; reusable vaping devices and liquids; oral nicotine pouches; and licensed nicotine-replacement medicines. A vape is a delivery device: its appearance does not establish whether it contains nicotine, cannabinoids or another substance.
- Routes
- Tobacco smoke and vaping aerosol are inhaled. Nicotine pouches release nicotine in the mouth, while licensed replacement products have product-specific oral, inhaled or skin routes. Combustion, aerosol exposure and medicinal nicotine should not be treated as equivalent exposures.
- UK legal classification
- Not MDA-classifiedNicotine and tobacco are regulated outside the Misuse of Drugs Act. Consumer nicotine vapes are covered by the Tobacco and Related Products Regulations 2016. UK sale and supply of single-use vapes, with or without nicotine, has been prohibited since 1 June 2025. Vaping Products Duty commenced on 1 October 2026. The Tobacco and Vapes Act received Royal Assent on 29 April 2026: its generational tobacco-sales restriction begins on 1 January 2027, while many initial sale and distribution provisions begin on 29 October 2026. Those future provisions are not yet effective at this review date; further controls depend on regulations.Check government source ↗
- Concise pharmacology
- Nicotine stimulates nicotinic acetylcholine receptors and reinforces repeated use through reward-related signalling. Dependence can develop across delivery products. Much of smoking-related cancer, lung disease and cardiovascular harm results from the toxic mixture produced by burning tobacco, rather than nicotine alone.
Main harms
Concise clinical and polydrug picture
Nicotine can cause nausea, dizziness, headache and an increased heart rate. Concentrated liquids can poison children or adults if swallowed or otherwise mishandled. Cough, throat irritation and other symptoms can follow vaping; collapse, seizures or difficulty breathing need emergency help.
Smoking causes major cancer, respiratory and cardiovascular disease. Switching completely from smoking to regulated nicotine vaping reduces exposure to many smoke toxicants. Vaping remains capable of sustaining dependence and its full long-term risks are uncertain. Continued smoking alongside vaping retains tobacco exposure; advice should support complete smoking cessation rather than imply that dual use eliminates risk.
Stopping or reducing nicotine can produce cravings, irritability, anxiety, low mood, poor concentration and sleep disturbance. Behavioural support and appropriate stop-smoking medicines can help. People who have stopped cigarettes using a vape should plan nicotine reduction without undermining their progress towards staying smoke-free.
Stopping cigarette smoking can increase blood concentrations of medicines such as clozapine because smoke-induced liver-enzyme activity falls. This is a tobacco-smoke interaction, not a nicotine interaction: switching to vaping or nicotine replacement still requires a medication review when relevant. Prescribing teams should also review changes when smoking resumes.
Smoking exposes users and others to combustion products. Vaping avoids combustion but still delivers an inhaled aerosol; unregulated or unidentified liquids add uncertainty. Keep nicotine liquids and oral products away from children. Evidence about regulated nicotine vapes must not be transferred to illicit THC or synthetic-cannabinoid products.
Current intelligence status
Assessment, confidence and direction
ONS estimates for 2025 show UK adult cigarette smoking continuing to decline and adult vaping in Great Britain broadly unchanged from 2024. These are different surveys and populations, not a single UK nicotine-use measure.
Reason: ONS, published 6 October 2026, estimates cigarette smoking among UK adults aged 18+ at 9.8% in 2025. Separately, 9.9% of adults aged 16+ in Great Britain used e-cigarettes daily or occasionally, similar to 10.0% in 2024. NHS England's 2023 school survey found 9% current vaping among 11–15-year-olds, unchanged from 2021; it is not a 2026 estimate. Age ranges, geography and survey definitions differ. High confidence applies to these defined survey estimates and the established smoking–vaping distinction, not to a complete long-term risk estimate for every product.
Principal source limits: APS smoking covers UK adults 18+; OPN vaping covers Great Britain adults 16+. The two surveys have different populations and definitions. School survey of England; current use includes regular and occasional use. These are 2023 observations, not a 2026 prevalence estimate.
Geography and reference periods are given in each linked source card below. The rating is an editorial evidence judgement, not a probability, clinical risk score or TD priority.The assessment reflects the latest linked evidence and is not a universal severity rating.
Operational implications
Evidence-supported prompts for professional response
Maintain two clear messages: help adults who smoke to stop combustible tobacco, and prevent children and non-smokers from starting nicotine use. Offer cessation support within drug, alcohol, mental-health and housing services. For young people, assess frequency, dependence, school access and safeguarding needs without equating experimentation with daily use. Record cigarette smoking, nicotine vaping and cannabis or unknown-drug vaping separately. Report suspected adverse reactions and product concerns through the MHRA Yellow Card scheme and local trading standards routes.
Record substance, sold identity, route, frequency and combinations; review physical, mental-health and dependence needs.
Use symptom-led assessment and escalate reduced consciousness, seizures, overheating, chest pain or severe agitation.
Triangulate treatment, mortality, testing, hospital and frontline evidence before assigning a local trend.
Related intelligence
Continue into connected platform evidence
Sources & limitations
Direct evidence links, reference periods and status
Adult smoking habits in the UK: 2025
Published6 Oct 2026Reference periodCalendar year 2025
APS smoking covers UK adults 18+; OPN vaping covers Great Britain adults 16+. The two surveys have different populations and definitions.Smoking, drinking and drug use among young people in England: electronic cigarette use
Published17 Oct 2024Reference periodEngland school pupils aged 11–15, 2023
School survey of England; current use includes regular and occasional use. These are 2023 observations, not a 2026 prevalence estimate.Vaping to quit smoking
PublishedCurrent online guidanceReference periodSmoking cessation and relative harms
Advice concerns nicotine vaping as an alternative to smoking; it does not establish the safety of illicit or unidentified vape contents.E-cigarettes: regulations for consumer products
PublishedCurrent online guidanceReference periodTobacco and Related Products Regulations 2016, as amended
Notification and regulatory compliance are not equivalent to medicinal authorisation or a guarantee that a product is harmless.Single-use vapes ban: information for businesses
Published20 Jan 2025; updated 3 Jul 2025Reference periodUK sale and supply prohibition from 1 Jun 2025
Covers single-use products with or without nicotine; it does not prohibit all vaping products.Tobacco and Vapes Act 2026
Published29 Apr 2026Reference periodCommencement differs by provision
Royal Assent is not the commencement date for every provision; sections 175 and 176 and any regulations determine when measures apply.Vaping Products Duty and Vaping Duty Stamps: force of law notice
PublishedUpdated 1 Oct 2026Reference periodDuty and stamp scheme from 1 Oct 2026
Transitional arrangements apply to stock released before commencement; fiscal controls do not assess product health risk.Considering drug interactions with smoking
Published31 Oct 2023; updated 8 Nov 2023Reference periodClinical medicine-interaction guidance
Medicine-specific assessment is required; most medicines do not require a change, while some have clinically important interactions.How to quit vaping
PublishedCurrent online guidanceReference periodNicotine withdrawal and cessation
Support should reflect age, dependence, previous cigarette use and individual circumstances.Smoking: secondary school health portal
PublishedSource page undatedReference periodNicotine effects and poisoning
Public information; suspected serious poisoning requires emergency clinical assessment.